9月8日，云顶新耀盘中上涨5.05%，报32.88港元，成交额1.38亿港元。
消息面上，公司于9月3日宣布，国家药品监督管理局已批准星必妥（艾曲帕米鼻喷雾剂）的新药上市许可申请，用于治疗成人阵发性室上性心动过速（PSVT）急性症状发作。星必妥是30余年来首款且唯一获批用于成人PSVT急性发作治疗的创新疗法，也是公司在心血管领域首个获批产品。该药采用鼻喷方式给药，可由患者院外自行使用，最快给药后5分钟起效，中位转复时间17.2分钟，填补国内PSVT院外应急自救空白。此次获批同时触发云顶新耀向Milestone Pharmaceuticals支付200万美元里程碑款项。中国PSVT患者估计为300万至600万人，星必妥有望成为公司新的商业化增长支点。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.